Literature DB >> 12639987

Spontaneous circulation of myeloid-lymphoid-initiating cells and SCID-repopulating cells in sickle cell crisis.

Christopher E D Lamming1, Lance Augustin, Mark Blackstad, Troy C Lund, Robert P Hebbel, Catherine M Verfaillie.   

Abstract

The only curative therapy for sickle cell disease (SCD) is allogeneic hematopoietic stem cell (HSC) transplantation. Gene therapy approaches for autologous HSC transplantation are being developed. Although earlier engraftment is seen when cells from GCSF-mobilized blood are transplanted than when bone marrow is transplanted, administration of GCSF to patients with SCD can cause significant morbidity. We tested whether primitive hematopoietic progenitors are spontaneously mobilized in the blood of patients with SCD during acute crisis (AC-SCD patients). The frequency of myeloid-lymphoid-initiating cells (ML-ICs) and SCID-repopulating cells (SRCs) was significantly higher in blood from AC-SCD patients than in blood from patients with steady-state SCD or from normal donors. The presence of SRCs in peripheral blood was not associated with detection of long-term culture-initiating cells, consistent with the notion that SRCs are more primitive than long-term culture-initiating cells. As ML-ICs and SRCs were both detected in blood of AC-SCD patients only, these assays may both measure primitive progenitors. The frequency of ML-ICs also correlated with increases in stem cell factor, GCSF, and IL-8 levels in AC-SCD compared with steady-state SCD and normal-donor sera. Because significant numbers of ML-ICs and SRCs are mobilized in the blood without exogenous cytokine treatment during acute crisis of SCD, collection of peripheral blood progenitors during crisis may yield a source of autologous HSCs suitable for ex-vivo correction by gene therapy approaches and subsequent transplantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639987      PMCID: PMC153763          DOI: 10.1172/JCI15956

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Evidence for stem cells in the peripheral blood of mice.

Authors:  J W GOODMAN; G S HODGSON
Journal:  Blood       Date:  1962-06       Impact factor: 22.113

2.  Circulating cytokines in sickle cell patients during steady state.

Authors:  H Croizat
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

3.  Bone-marrow transplantation in a patient with sickle-cell anemia.

Authors:  F L Johnson; A T Look; J Gockerman; M R Ruggiero; L Dalla-Pozza; F T Billings
Journal:  N Engl J Med       Date:  1984-09-20       Impact factor: 91.245

4.  In vivo administration of stem cell factor to mice increases the absolute number of pluripotent hematopoietic stem cells.

Authors:  D M Bodine; N E Seidel; K M Zsebo; D Orlic
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

5.  Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols.

Authors:  A Larochelle; J Vormoor; T Lapidot; G Sher; T Furukawa; Q Li; L D Shultz; N F Olivieri; G Stamatoyannopoulos; J E Dick
Journal:  Hum Mol Genet       Date:  1995-02       Impact factor: 6.150

6.  Radioprotection of mice by recombinant rat stem cell factor.

Authors:  K M Zsebo; K A Smith; C A Hartley; M Greenblatt; K Cooke; W Rich; I K McNiece
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Mortality in sickle cell disease. Life expectancy and risk factors for early death.

Authors:  O S Platt; D J Brambilla; W F Rosse; P F Milner; O Castro; M H Steinberg; P P Klug
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

8.  Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability.

Authors:  L Laterveer; I J Lindley; M S Hamilton; R Willemze; W E Fibbe
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

9.  Sustained human hematopoiesis in sheep transplanted in utero during early gestation with fractionated adult human bone marrow cells.

Authors:  E F Srour; E D Zanjani; J E Brandt; T Leemhuis; R A Briddell; N A Heerema; R Hoffman
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

10.  Changes in c-Kit expression and effects of SCF during differentiation of human erythroid progenitor cells.

Authors:  N Uoshima; M Ozawa; S Kimura; K Tanaka; K Wada; Y Kobayashi; M Kondo
Journal:  Br J Haematol       Date:  1995-09       Impact factor: 6.998

View more
  14 in total

Review 1.  Mast cell-neural interactions contribute to pain and itch.

Authors:  Kalpna Gupta; Ilkka T Harvima
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

2.  To stay or to leave: Stem cells and progenitor cells navigating the S1P gradient.

Authors:  Jingjing Liu; Andrew Hsu; Jen-Fu Lee; Daniel E Cramer; Menq-Jer Lee
Journal:  World J Biol Chem       Date:  2011-01-26

3.  Mast cell activation contributes to sickle cell pathobiology and pain in mice.

Authors:  Lucile Vincent; Derek Vang; Julia Nguyen; Mihir Gupta; Kathryn Luk; Marna E Ericson; Donald A Simone; Kalpna Gupta
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

Review 4.  An emerging link in stem cell mobilization between activation of the complement cascade and the chemotactic gradient of sphingosine-1-phosphate.

Authors:  Mariusz Z Ratajczak; Sylwia Borkowska; Janina Ratajczak
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-09-03       Impact factor: 3.072

5.  Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex.

Authors:  M Z Ratajczak; H Lee; M Wysoczynski; W Wan; W Marlicz; M J Laughlin; M Kucia; A Janowska-Wieczorek; J Ratajczak
Journal:  Leukemia       Date:  2010-04-01       Impact factor: 11.528

6.  Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion.

Authors:  Shin-Young Park; Alessandro Matte; Yookyung Jung; Jina Ryu; Wilson Babu Anand; Eun-Young Han; Min Liu; Carmine Carbone; Davide Melisi; Takashi Nagasawa; Joseph J Locascio; Charles P Lin; Leslie E Silberstein; Lucia De Franceschi
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

7.  Further evidence that paroxysmal nocturnal haemoglobinuria is a disorder of defective cell membrane lipid rafts.

Authors:  Mariusz Z Ratajczak; Sylwia Borkowska; Kasia Mierzejewska; Magda Kucia; Ewa Mendek-Czajkowska; Malwina Suszynska; Vivek A Sharma; Andrzej Deptala; Wechao Song; Uwe Platzbecker; Loree Larratt; Anna Janowska-Wieczorek; Jarek Maciejewski; Janina Ratajczak
Journal:  J Cell Mol Med       Date:  2015-05-29       Impact factor: 5.310

8.  Sphingosine-1-phosphate-mediated mobilization of hematopoietic stem/progenitor cells during intravascular hemolysis requires attenuation of SDF-1-CXCR4 retention signaling in bone marrow.

Authors:  Kasia Mierzejewska; Yuri M Klyachkin; Janina Ratajczak; Ahmed Abdel-Latif; Magda Kucia; Mariusz Z Ratajczak
Journal:  Biomed Res Int       Date:  2013-12-29       Impact factor: 3.411

9.  Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.

Authors:  Chantal Lagresle-Peyrou; François Lefrère; Elisa Magrin; Jean-Antoine Ribeil; Oriana Romano; Leslie Weber; Alessandra Magnani; Hanem Sadek; Clémence Plantier; Aurélie Gabrion; Brigitte Ternaux; Tristan Félix; Chloé Couzin; Aurélie Stanislas; Jean-Marc Tréluyer; Lionel Lamhaut; Laure Joseph; Marianne Delville; Annarita Miccio; Isabelle André-Schmutz; Marina Cavazzana
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

10.  Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Authors:  Farid Boulad; Tsiporah Shore; Koen van Besien; Caterina Minniti; Mihaela Barbu-Stevanovic; Sylvie Wiener Fedus; Fabiana Perna; June Greenberg; Danielle Guarneri; Vijay Nandi; Audrey Mauguen; Karina Yazdanbakhsh; Michel Sadelain; Patricia A Shi
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.